Clinical Outcome of Colorectal Cancer Patients with Concomitant Hypertension: A Systematic Review and Meta-Analysis.

Autor:	Sur D; Department of Medical Oncology, University of Medicine and Pharmacy 'Iuliu Haţieganu', 400012 Cluj-Napoca, Romania.; Department of Medical Oncology, The Oncology Institute 'Prof. Dr. Ion Chiricuţă', 400015 Cluj-Napoca, Romania., Coroama CI; Department of Medical Oncology, The Oncology Institute 'Prof. Dr. Ion Chiricuţă', 400015 Cluj-Napoca, Romania., Audisio A; Department of Digestive Oncology, Institute Jules Bordet, The Brussels University Hospital, 1070 Brussels, Belgium., Fazio R; Department of Digestive Oncology, Institute Jules Bordet, The Brussels University Hospital, 1070 Brussels, Belgium., Coroama M; Department of Pathophysiology, Faculty of Medicine, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 4-6 Victor Babeş Street, 400012 Cluj-Napoca, Romania.; Department of Cardiology, 'Niculae Stancioiu' Heart Institute, 400001 Cluj-Napoca, Romania., Lungulescu CV; Department of Medical Oncology, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania.
Jazyk:	angličtina
Zdroj:	Journal of personalized medicine [J Pers Med] 2024 May 14; Vol. 14 (5). Date of Electronic Publication: 2024 May 14.
DOI:	10.3390/jpm14050520
Abstrakt:	Background: Arterial hypertension is regarded as a possible biomarker of treatment efficacy in colorectal cancer. Also, extended anti-angiogenic use in the metastatic treatment of the colorectal neoplasm may result in elevated blood pressure. We carried out a systematic review and meta-analysis to assess the clinical outcome of colorectal cancer patients with concomitant hypertension (HTN). Methods: We conducted a systematic search on Embase, Web of Science, Scopus, PubMed (Medline), the Cochrane Library, and CINAHL from inception until October 2023 for articles that addressed the relationship between HTN and progressive free survival (PFS), overall survival (OS), and overall response rate (ORR) for the first and second line of systemic therapy in patients with metastatic colorectal cancer. Results: Eligibility criteria were met by 16 articles out of 802 screened studies. Pooled analysis showed that HTN was associated with significantly improved PFS (HR: 0.507, 95% CI: 0.460-0.558, p ≤ 0.001) and OS (HR: 0.677, 95% CI: 0.592-0.774, p ≤ 0.001) in patients with metastatic colorectal cancer. In addition, the pooled RR of HTN for the ORR (RR: 1.28, 95% CI: 1.108-1.495, p = 0.001) suggests that HTN could be a predictive factor of ORR in patients with metastatic colorectal cancer. Conclusions: Elevated blood pressure is associated with better clinical outcomes in patients with metastatic colorectal cancer.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu